Key result
The small-molecule MEK inhibitor zapnometinib demonstrated antiviral efficacy against both influenza A virus and SARS-CoV-2 by targeting the Raf/MEK/ERK signaling pathway.
This editorial discusses antiviral options for emerging viral diseases, highlighting the potential of targeting host cellular signaling pathways like Raf/MEK/ERK.
infections (Kumar et al., 2018;Asha et al., 2019;Asha et al., 2023). Viruses often hijack cellular 38 machinery and utilize host cellular signaling pathways during their replication cycle (Lekshmi et al., 39 2023). The research article by Hoffmann et al. also demonstrated that two crucial viral pathogens, 40 influenza viruses and SARS-CoV-2, rely on the Raf/MEK/ERK signaling pathway for their replication 41 (Hoffmann et al., 2023). This was proved using a small-molecule MEK inhibitor zapnometinib side by 42 side against both influenza A virus (IAV) and SARS-CoV2 to test its antiviral efficacy.
No takes yet. Share an insight, caveat, or question.
Meseko et al. (2024) conducted an editorial in Viral diseases (Influenza A virus and SARS-CoV-2). Zapnometinib was evaluated on Antiviral efficacy. The small-molecule MEK inhibitor zapnometinib demonstrated antiviral efficacy against both influenza A virus and SARS-CoV-2 by targeting the Raf/MEK/ERK signaling pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: